• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ALXN

ALXN

Alexion Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD182.50

+0.00 (+0.00%)

Company Profile

CEO

Ludwig Hantson

IPO Date

1996-02-01

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$181.04

Prev. Close

$182.50

Day Low

$180.21

Day High

$182.67

52W Low

$99.91

52W High

$187.45

Volume

0.00M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

49.3%

Avg Negative

2.2%

Avg Neutral

48.5%

News Feed

Alexion (ALXN) Reports Positive Data on Ultomiris From gMG Study

Zacks Investment Research·7/16/2021·↑ positive

Alexion's Ultomiris Shows Compelling, Durable Efficacy In Rare Muscle Weakness Disorder

Benzinga·7/16/2021·↑ positive

Why Alexion Pharmaceuticals (ALXN) is a Top Momentum Stock for the Long-Term

Zacks Investment Research·7/15/2021·↑ positive

ALXN or GMAB: Which Is the Better Value Stock Right Now?

Zacks Investment Research·7/5/2021·↓ negative

Apellis Pharmaceuticals Goes After Alexion Blood Disorder Drugs

GuruFocus·6/10/2021·↑ positive

Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Business Wire·6/7/2021·↑ positive

Alexion Shareholders Approve Acquisition by AstraZeneca

Business Wire·5/11/2021·↑ positive

Alexion Pharmaceuticals (ALXN) Beats Q1 Earnings and Revenue Estimates

Zacks Investment Research·4/30/2021·↑ positive

Alexion (ALXN) Tops Q1 Earnings, Merger With AstraZeneca On Track

Zacks Investment Research·4/30/2021·↑ positive

Recap: Alexion Pharmaceuticals Q1 Earnings

Benzinga·4/30/2021·↑ positive